1
|
Quadros HC, Herrmann L, Manaranche J, Paloque L, Borges-Silva MC, Dziwornu GA, D'Alessandro S, Chibale K, Basilico N, Benoit-Vical F, Tsogoeva SB, Moreira DRM. Characterization of antimalarial activity of artemisinin-based hybrid drugs. Antimicrob Agents Chemother 2024; 68:e0014324. [PMID: 38899927 PMCID: PMC11232401 DOI: 10.1128/aac.00143-24] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2024] [Accepted: 06/01/2024] [Indexed: 06/21/2024] Open
Abstract
In response to the spread of artemisinin (ART) resistance, ART-based hybrid drugs were developed, and their activity profile was characterized against drug-sensitive and drug-resistant Plasmodium falciparum parasites. Two hybrids were found to display parasite growth reduction, stage-specificity, speed of activity, additivity of activity in drug combinations, and stability in hepatic microsomes of similar levels to those displayed by dihydroartemisinin (DHA). Conversely, the rate of chemical homolysis of the peroxide bonds is slower in hybrids than in DHA. From a mechanistic perspective, heme plays a central role in the chemical homolysis of peroxide, inhibiting heme detoxification and disrupting parasite heme redox homeostasis. The hybrid exhibiting slow homolysis of peroxide bonds was more potent in reducing the viability of ART-resistant parasites in a ring-stage survival assay than the hybrid exhibiting fast homolysis. However, both hybrids showed limited activity against ART-induced quiescent parasites in the quiescent-stage survival assay. Our findings are consistent with previous results showing that slow homolysis of peroxide-containing drugs may retain activity against proliferating ART-resistant parasites. However, our data suggest that this property does not overcome the limited activity of peroxides in killing non-proliferating parasites in a quiescent state.
Collapse
Affiliation(s)
| | - Lars Herrmann
- Organic Chemistry Chair I and Interdisciplinary Center for Molecular Materials (ICMM), Friedrich-Alexander-Universität of Erlangen-Nürnberg, Erlangen, Germany
| | - Jeanne Manaranche
- LCC-CNRS, Laboratoire de Chimie de Coordination, Université de Toulouse, CNRS, Toulouse, France
- MAAP, New Antimalarial Molecules and Pharmacological Approaches, Inserm ERL 1289, Toulouse, France
- Institut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, Université Toulouse III - Paul Sabatier (UPS), Toulouse, France
| | - Lucie Paloque
- LCC-CNRS, Laboratoire de Chimie de Coordination, Université de Toulouse, CNRS, Toulouse, France
- MAAP, New Antimalarial Molecules and Pharmacological Approaches, Inserm ERL 1289, Toulouse, France
- Institut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, Université Toulouse III - Paul Sabatier (UPS), Toulouse, France
| | | | - Godwin Akpeko Dziwornu
- Drug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch, South Africa
| | - Sarah D'Alessandro
- Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Milan, Italy
| | - Kelly Chibale
- Drug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch, South Africa
- South African Medical Research Council Drug Discovery and Development Research Unit, Department of Chemistry and Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Rondebosch, South Africa
| | - Nicoletta Basilico
- Dipartimento di Scienze Biomediche, Chirurgiche e Odontoiatriche, Chirurgiche e Odontoiatriche, Universitá degli Studi di Milano, Milan, Italy
| | - Françoise Benoit-Vical
- LCC-CNRS, Laboratoire de Chimie de Coordination, Université de Toulouse, CNRS, Toulouse, France
- MAAP, New Antimalarial Molecules and Pharmacological Approaches, Inserm ERL 1289, Toulouse, France
- Institut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, Université Toulouse III - Paul Sabatier (UPS), Toulouse, France
| | - Svetlana B. Tsogoeva
- Organic Chemistry Chair I and Interdisciplinary Center for Molecular Materials (ICMM), Friedrich-Alexander-Universität of Erlangen-Nürnberg, Erlangen, Germany
| | | |
Collapse
|
2
|
Rathi K, Shukla M, Hassam M, Shrivastava R, Rawat V, Prakash Verma V. Recent advances in the synthesis and antimalarial activity of 1,2,4-trioxanes. Bioorg Chem 2024; 143:107043. [PMID: 38134523 DOI: 10.1016/j.bioorg.2023.107043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2023] [Revised: 11/29/2023] [Accepted: 12/15/2023] [Indexed: 12/24/2023]
Abstract
The increasing resistance of various malarial parasite strains to drugs has made the production of a new, rapid-acting, and efficient antimalarial drug more necessary, as the demand for such drugs is growing rapidly. As a major global health concern, various methods have been implemented to address the problem of drug resistance, including the hybrid drug concept, combination therapy, the development of analogues of existing medicines, and the use of drug resistance reversal agents. Artemisinin and its derivatives are currently used against multidrug- resistant P. falciparum species. However, due to its natural origin, its use has been limited by its scarcity in natural resources. As a result, finding a substitute becomes more crucial, and the peroxide group in artemisinin, responsible for the drugs biological action in the form of 1,2,4-trioxane, may hold the key to resolving this issue. The literature suggests that 1,2,4-trioxanes have the potential to become an alternative to current malaria drugs, as highlighted in this review. This is why 1,2,4-trioxanes and their derivatives have been synthesized on a large scale worldwide, as they have shown promising antimalarial activity in vivo and in vitro against Plasmodium species. Consequently, the search for a more convenient, environment friendly, sustainable, efficient, and effective synthetic pathway for the synthesis of 1,2,4-trioxanes continues. The aim of this work is to provide a comprehensive analysis of the synthesis and mechanism of action of 1,2,4-trioxanes. This systematic review highlights the most recent summaries of derivatives of 1,2,4-trioxane compounds and dimers with potential antimalarial activity from January 1988 to 2023.
Collapse
Affiliation(s)
- Komal Rathi
- Department of Chemistry, Banasthali University, Banasthali Newai 304022, Rajasthan, India
| | - Monika Shukla
- Department of Chemistry, Banasthali University, Banasthali Newai 304022, Rajasthan, India
| | | | - Rahul Shrivastava
- Department of Chemistry, Manipal University Jaipur, Jaipur (Rajasthan), VPO- Dehmi-Kalan, Off Jaipur-Ajmer Express Way, Jaipur, Rajasthan 30300, India
| | - Varun Rawat
- School of Chemistry, Tel Aviv University, Tel Aviv 6997801, Israel.
| | - Ved Prakash Verma
- Department of Chemistry, Banasthali University, Banasthali Newai 304022, Rajasthan, India.
| |
Collapse
|
3
|
Serafin P, Kleczkowska P. Bombesins: A New Frontier in Hybrid Compound Development. Pharmaceutics 2023; 15:2597. [PMID: 38004575 PMCID: PMC10674911 DOI: 10.3390/pharmaceutics15112597] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2023] [Revised: 11/03/2023] [Accepted: 11/06/2023] [Indexed: 11/26/2023] Open
Abstract
Recently, bombesin (BN) and its analogs have attracted much attention as excellent anticancer agents because they interact with specific receptors widely distributed on the surface of various cancer cells. However, their biological properties proceed far beyond this, given a broad spectrum of activity. Bombesin receptor ligands are effective drugs for the treatment of rheumatoid arthritis or gastrointestinal diseases. However, most diseases are complex, and the use of polytherapy may lead to pharmacokinetic and pharmacodynamic drug-drug interactions, resulting in side effects. Therefore, there is a need to develop effective compounds that also contain BN or its analogs, which are combined with other structural entities, thus generating a so-called hybrid drug. Hybrid drugs that contain bombesin pharmacophore(s) may be proposed as a solution to the problem of polytherapy or the lack of an effective cure. Such structures have now demonstrated the desired efficacy, though information on these aforementioned compounds is relatively scarce. Therefore, our paper aims to encourage researchers to focus on bombesins. Herein, we indicate that the hybrid approach should also be firmly applied to bombesins and the BN receptor family. This paper's structure is divided into two main sections demonstrating bombesins and their properties, as well as recent data on bombesin-based hybrid compounds and their potential usefulness in medicine. Overall, it refers to the discovery and synthesis of modified bombesin-based hybrid compounds.
Collapse
Affiliation(s)
- Pawel Serafin
- Military Institute of Hygiene and Epidemiology, 01-163 Warsaw, Poland;
| | - Patrycja Kleczkowska
- Military Institute of Hygiene and Epidemiology, 01-163 Warsaw, Poland;
- Maria Sklodowska-Curie, Medical Academy in Warsaw, Solidarnosci 12 Str., 03-411 Warsaw, Poland
| |
Collapse
|
4
|
Antimalarial activity assay of artesunate-3-chloro-4(4-chlorophenoxy) aniline in vitro and in mice models. Parasitol Res 2023; 122:979-988. [PMID: 36859621 PMCID: PMC9977633 DOI: 10.1007/s00436-023-07801-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2022] [Accepted: 02/20/2023] [Indexed: 03/03/2023]
Abstract
The global spread of multi-drug resistant P. falciparum, P. vivax, and P. malariae strains and absence of long-term effective vaccine makes chemotherapy the mainstay of malaria control strategies in endemic settings. The Mossman's assay and the Organization for Economic Co-operation and Development (OECD), 2001 guideline 423, were used to determine the cytotoxicity and acute oral toxicity of a novel hybrid drug, artesunate-3-Chloro-4(4-chlorophenoxy) aniline (ATSA), in vitro and in vivo, respectively. A modified Desjardins method was used to screen for antiplasmodial activity using P. falciparum (3D7 and W2) strains in vitro. The Peter's 4-day suppressive tests (4DTs) was used to evaluate the in vivo antimalaria activity using P. berghei ANKA strain, lumefantrine resistant (LuR), and piperaquine resistant (PQR) P. berghei lines. In silico prediction of absorption, distribution, metabolism, excretion, and toxicity (ADMET) profiles was assayed using PreADMET online prediction tool. The reference drug in all experiments was artesunate (ATS). Statistical significance between ATSA's activities in treated and control mice was evaluated by one-way analysis of variance (ANOVA). Results show that inhibitory concentrations-50 (IC50) of ATSA is 11.47 ± 1.3 (3D7) and 1.45 ± 0.26 (W2) against 4.66 ± 0.93 (3D7) and 0.60 ± 0.15 (W2) ng/ml of ATS with a selective index of 2180.91(3D7) and a therapeutic index (TI) of > 71). No mortalities were observed in acute oral toxicity assays and mean weight differences for test and controls were statistically insignificant (P > 0.05). The in vivo activity of ATSA was above 40% with effective dosage-50 (ED50) of 4.211, 2.601, and 3.875 mg/kg body weight against P. berghei ANKA, LuR, and PQR lines, respectively. The difference between treated and control mice was statistically significant (P < 0.05). ATSA has high intestinal absorption (HIA) > 95% and has medium human ether-a-go-go related gene (hERG) K+ channel inhibition risks. Preclinical and clinical studies on ATSA are recommended to evaluate its value in developing novel drugs for future management of multi-drug resistant malaria parasites.
Collapse
|
5
|
Synthesis, in-vitro biological evaluation, and molecular docking study of novel spiro-β-lactam-isatin hybrids. Med Chem Res 2022. [DOI: 10.1007/s00044-022-02898-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
6
|
Li Y, Loureiro A, Nguyen M, Laurent M, Bijani C, Benoit‐Vical F, Robert A, Liu Y, Meunier B. Synthesis and Antimalarial Activities of New Hybrid Atokel Molecules. ChemistryOpen 2022; 11:e202200064. [PMID: 35543215 PMCID: PMC9092290 DOI: 10.1002/open.202200064] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2022] [Revised: 03/31/2022] [Indexed: 11/11/2022] Open
Abstract
The currently spreading resistance of the malaria parasite Plasmodium falciparum to artemisinin-based combination therapies makes an urgent need for new efficient drugs. Aiming to kill artemisinin-resistant Plasmodium, a series of novel hybrid drugs named Atokels were synthesized and characterized. Atokels are based on an 8-amino- or 8-hydroxyquinoline entity covalently bound to a 1,4-naphthoquinone through a polyamine linker. These drugs have been designed to target the parasite mitochondrion by their naphthoquinone moiety reminiscent of the antimalarial drug atovaquone, and to trigger a damaging oxidative stress due to their ability to chelate metal ions in order to generate redox active complexes in situ. The most effective Atokel drug shown a promising antimalarial activity (IC50 =622 nm on an artemisinin-resistant P. falciparum strain) and no cytotoxicity at 50 μm indicating a specific antiplasmodial mode of action.
Collapse
Affiliation(s)
- Youzhi Li
- Guangdong University of TechnologySchool of Chemical Engineering and Light Industryno. 100 Waihuan Xi road Education Mega CenterGuangzhou510006P. R. China
| | - Anthony Loureiro
- Laboratoire de Chimie de Coordination du CNRSLCC–CNRSUniversité de ToulouseUniversité Paul Sabatier205 route de Narbonne, BP 4409931077Toulouse cedex 4France
- New antimalarial molecules and pharmacological approachesMAAPInserm ER1289ToulouseFrance
| | - Michel Nguyen
- Laboratoire de Chimie de Coordination du CNRSLCC–CNRSUniversité de ToulouseUniversité Paul Sabatier205 route de Narbonne, BP 4409931077Toulouse cedex 4France
- New antimalarial molecules and pharmacological approachesMAAPInserm ER1289ToulouseFrance
- Institut de Pharmacologie et de Biologie StructuraleIPBSCNRSUniversité de ToulouseUniversité Paul Sabatier205 route de Narbonne, BP 6418231077Toulouse cedex 4France
| | - Marion Laurent
- Laboratoire de Chimie de Coordination du CNRSLCC–CNRSUniversité de ToulouseUniversité Paul Sabatier205 route de Narbonne, BP 4409931077Toulouse cedex 4France
- New antimalarial molecules and pharmacological approachesMAAPInserm ER1289ToulouseFrance
- Institut de Pharmacologie et de Biologie StructuraleIPBSCNRSUniversité de ToulouseUniversité Paul Sabatier205 route de Narbonne, BP 6418231077Toulouse cedex 4France
| | - Christian Bijani
- Laboratoire de Chimie de Coordination du CNRSLCC–CNRSUniversité de ToulouseUniversité Paul Sabatier205 route de Narbonne, BP 4409931077Toulouse cedex 4France
| | - Françoise Benoit‐Vical
- Laboratoire de Chimie de Coordination du CNRSLCC–CNRSUniversité de ToulouseUniversité Paul Sabatier205 route de Narbonne, BP 4409931077Toulouse cedex 4France
- New antimalarial molecules and pharmacological approachesMAAPInserm ER1289ToulouseFrance
- Institut de Pharmacologie et de Biologie StructuraleIPBSCNRSUniversité de ToulouseUniversité Paul Sabatier205 route de Narbonne, BP 6418231077Toulouse cedex 4France
| | - Anne Robert
- Laboratoire de Chimie de Coordination du CNRSLCC–CNRSUniversité de ToulouseUniversité Paul Sabatier205 route de Narbonne, BP 4409931077Toulouse cedex 4France
- New antimalarial molecules and pharmacological approachesMAAPInserm ER1289ToulouseFrance
| | - Yan Liu
- Guangdong University of TechnologySchool of Chemical Engineering and Light Industryno. 100 Waihuan Xi road Education Mega CenterGuangzhou510006P. R. China
| | - Bernard Meunier
- Guangdong University of TechnologySchool of Chemical Engineering and Light Industryno. 100 Waihuan Xi road Education Mega CenterGuangzhou510006P. R. China
- Laboratoire de Chimie de Coordination du CNRSLCC–CNRSUniversité de ToulouseUniversité Paul Sabatier205 route de Narbonne, BP 4409931077Toulouse cedex 4France
- New antimalarial molecules and pharmacological approachesMAAPInserm ER1289ToulouseFrance
| |
Collapse
|
7
|
Yang J, Wang Y, Guan W, Su W, Li G, Zhang S, Yao H. Spiral molecules with antimalarial activities: A review. Eur J Med Chem 2022; 237:114361. [DOI: 10.1016/j.ejmech.2022.114361] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2022] [Revised: 04/03/2022] [Accepted: 04/04/2022] [Indexed: 11/04/2022]
|
8
|
Simwela NV, Waters AP. Current status of experimental models for the study of malaria. Parasitology 2022; 149:1-22. [PMID: 35357277 PMCID: PMC9378029 DOI: 10.1017/s0031182021002134] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2021] [Revised: 12/07/2021] [Accepted: 12/08/2021] [Indexed: 01/09/2023]
Abstract
Infection by malaria parasites (Plasmodium spp.) remains one of the leading causes of morbidity and mortality, especially in tropical regions of the world. Despite the availability of malaria control tools such as integrated vector management and effective therapeutics, these measures have been continuously undermined by the emergence of vector resistance to insecticides or parasite resistance to frontline antimalarial drugs. Whilst the recent pilot implementation of the RTS,S malaria vaccine is indeed a remarkable feat, highly effective vaccines against malaria remain elusive. The barriers to effective vaccines result from the complexity of both the malaria parasite lifecycle and the parasite as an organism itself with consequent major gaps in our understanding of their biology. Historically and due to the practical and ethical difficulties of working with human malaria infections, research into malaria parasite biology has been extensively facilitated by animal models. Animals have been used to study disease pathogenesis, host immune responses and their (dys)regulation and further disease processes such as transmission. Moreover, animal models remain at the forefront of pre-clinical evaluations of antimalarial drugs (drug efficacy, mode of action, mode of resistance) and vaccines. In this review, we discuss commonly used animal models of malaria, the parasite species used and their advantages and limitations which hinder their extrapolation to actual human disease. We also place into this context the most recent developments such as organoid technologies and humanized mice.
Collapse
Affiliation(s)
- Nelson V. Simwela
- Institute of Infection, Immunity & Inflammation, Wellcome Centre for Integrative Parasitology, University of Glasgow, Glasgow, UK
| | - Andrew P. Waters
- Institute of Infection, Immunity & Inflammation, Wellcome Centre for Integrative Parasitology, University of Glasgow, Glasgow, UK
| |
Collapse
|
9
|
Studies of Potency and Efficacy of an Optimized Artemisinin-Quinoline Hybrid against Multiple Stages of the Plasmodium Life Cycle. Pharmaceuticals (Basel) 2021; 14:ph14111129. [PMID: 34832911 PMCID: PMC8620906 DOI: 10.3390/ph14111129] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2021] [Revised: 11/02/2021] [Accepted: 11/03/2021] [Indexed: 11/23/2022] Open
Abstract
A recently developed artemisinin-quinoline hybrid, named 163A, has been shown to display potent activity against the asexual blood stage of Plasmodium, the malaria parasite. In this study, we determined its in vitro cytotoxicity to mammalian cells, its potency to suppress P. berghei hepatic infection and to decrease the viability of P. falciparum gametocytes, in addition to determining whether the drug exhibits efficacy of a P. berghei infection in mice. This hybrid compound has a low level of cytotoxicity to mammalian cells and, conversely, a high level of selectivity. It is potent in the prevention of hepatic stage development as well as in killing gametocytes, denoting a potential blockage of malaria transmission. The hybrid presents a potent inhibitory activity for beta-hematin crystal formation, in which subsequent assays revealed that its endoperoxide component undergoes bioactivation by reductive reaction with ferrous heme towards the formation of heme-drug adducts; in parallel, the 7-chloroquinoline component has binding affinity for ferric hemin. Both structural components of the hybrid co-operate to enhance the inhibition of beta-hematin, and this bitopic ligand property is essential for arresting the growth of asexual blood parasites. We demonstrated the in vivo efficacy of the hybrid as an erythrocytic schizonticide agent in comparison to a chloroquine/artemisinin combination therapy. Collectively, the findings suggest that the bitopic property of the hybrid is highly operative on heme detoxification suppression, and this provides compelling evidence for explaining the action of the hybrid on the asexual blood stage. For sporozoite and gametocyte stages, the hybrid conserves the potency typically observed for endoperoxide drugs, and this is possibly achieved due to the redox chemistry of endoperoxide components with ferrous heme.
Collapse
|
10
|
Woodley CM, Amado PSM, Cristiano MLS, O'Neill PM. Artemisinin inspired synthetic endoperoxide drug candidates: Design, synthesis, and mechanism of action studies. Med Res Rev 2021; 41:3062-3095. [PMID: 34355414 DOI: 10.1002/med.21849] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2020] [Revised: 01/15/2021] [Accepted: 07/03/2021] [Indexed: 12/13/2022]
Abstract
Artemisinin combination therapies (ACTs) have been used as the first-line treatments against Plasmodium falciparum malaria for decades. Recent advances in chemical proteomics have shed light on the complex mechanism of action of semi-synthetic artemisinin (ARTs), particularly their promiscuous alkylation of parasite proteins via previous heme-mediated bioactivation of the endoperoxide bond. Alarmingly, the rise of resistance to ART in South East Asia and the synthetic limitations of the ART scaffold have pushed the course for the necessity of fully synthetic endoperoxide-based antimalarials. Several classes of synthetic endoperoxide antimalarials have been described in literature utilizing various endoperoxide warheads including 1,2-dioxanes, 1,2,4-trioxanes, 1,2,4-trioxolanes, and 1,2,4,5-tetraoxanes. Two of these classes, the 1,2,4-trioxolanes (arterolane and artefenomel) and the 1,2,4,5-tetraoxanes (N205 and E209) based antimalarials, have been explored extensively and are still in active development. In contrast, the most recent publication pertaining to the development of the 1,2-dioxane, Arteflene, and 1,2,4-trioxanes fenozan-50F, DU1301, and PA1103/SAR116242 was published in 2008. This review summarizes the synthesis, biological and clinical evaluation, and mechanistic studies of the most developed synthetic endoperoxide antimalarials, providing an update on those classes still in active development.
Collapse
Affiliation(s)
| | - Patrícia S M Amado
- Department of Chemistry, University of Liverpool, Liverpool, UK.,Center of Marine Sciences (CCMAR), University of Algarve, Faro, Portugal.,Department of Chemistry and Pharmacy, Faculdade de Ciências e Tecnologia, University of Algarve, Faro, Portugal
| | - Maria L S Cristiano
- Center of Marine Sciences (CCMAR), University of Algarve, Faro, Portugal.,Department of Chemistry and Pharmacy, Faculdade de Ciências e Tecnologia, University of Algarve, Faro, Portugal
| | - Paul M O'Neill
- Department of Chemistry, University of Liverpool, Liverpool, UK
| |
Collapse
|
11
|
Wu YJ, Meanwell NA. Geminal Diheteroatomic Motifs: Some Applications of Acetals, Ketals, and Their Sulfur and Nitrogen Homologues in Medicinal Chemistry and Drug Design. J Med Chem 2021; 64:9786-9874. [PMID: 34213340 DOI: 10.1021/acs.jmedchem.1c00790] [Citation(s) in RCA: 24] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Acetals and ketals and their nitrogen and sulfur homologues are often considered to be unconventional and potentially problematic scaffolding elements or pharmacophores for the design of orally bioavailable drugs. This opinion is largely a function of the perception that such motifs might be chemically unstable under the acidic conditions of the stomach and upper gastrointestinal tract. However, even simple acetals and ketals, including acyclic molecules, can be sufficiently robust under acidic conditions to be fashioned into orally bioavailable drugs, and these structural elements are embedded in many effective therapeutic agents. The chemical stability of molecules incorporating geminal diheteroatomic motifs can be modulated by physicochemical design principles that include the judicious deployment of proximal electron-withdrawing substituents and conformational restriction. In this Perspective, we exemplify geminal diheteroatomic motifs that have been utilized in the discovery of orally bioavailable drugs or drug candidates against the backdrop of understanding their potential for chemical lability.
Collapse
Affiliation(s)
- Yong-Jin Wu
- Small Molecule Drug Discovery, Bristol Myers Squibb Research and Early Development, 100 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Nicholas A Meanwell
- Department of Discovery and Chemistry and Molecular Technologies, Bristol-Myers Squibb PRI, PO Box 4000, Princeton, New Jersey 08543-4000, United States
| |
Collapse
|
12
|
Rout UK, Sanket AS, Sisodia BS, Mohapatra PK, Pati S, Kant R, Dwivedi GR. A Comparative Review on Current and Future Drug Targets Against Bacteria & Malaria. Curr Drug Targets 2021; 21:736-775. [PMID: 31995004 DOI: 10.2174/1389450121666200129103618] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2019] [Revised: 12/13/2019] [Accepted: 12/20/2019] [Indexed: 11/22/2022]
Abstract
Long before the discovery of drugs like 'antibiotic and anti-parasitic drugs', the infectious diseases caused by pathogenic bacteria and parasites remain as one of the major causes of morbidity and mortality in developing and underdeveloped countries. The phenomenon by which the organism exerts resistance against two or more structurally unrelated drugs is called multidrug resistance (MDR) and its emergence has further complicated the treatment scenario of infectious diseases. Resistance towards the available set of treatment options and poor pipeline of novel drug development puts an alarming situation. A universal goal in the post-genomic era is to identify novel targets/drugs for various life-threatening diseases caused by such pathogens. This review is conceptualized in the backdrop of drug resistance in two major pathogens i.e. "Pseudomonas aeruginosa" and "Plasmodium falciparum". In this review, the available targets and key mechanisms of resistance of these pathogens have been discussed in detail. An attempt has also been made to analyze the common drug targets of bacteria and malaria parasite to overcome the current drug resistance scenario. The solution is also hypothesized in terms of a present pipeline of drugs and efforts made by scientific community.
Collapse
Affiliation(s)
- Usha K Rout
- Microbiology Department, ICMR-Regional Medical Research Centre, Bhubaneswar-751023, India
| | | | - Brijesh S Sisodia
- Regional Ayurveda Research Institute for Drug Development, Gwalior-474 009, India
| | | | - Sanghamitra Pati
- Microbiology Department, ICMR-Regional Medical Research Centre, Bhubaneswar-751023, India
| | - Rajni Kant
- ICMR-Regional Medical Research Centre, Gorakhpur, Uttar Pradesh- 273013, India
| | - Gaurav R Dwivedi
- ICMR-Regional Medical Research Centre, Gorakhpur, Uttar Pradesh- 273013, India
| |
Collapse
|
13
|
Sharma B, Singh P, Singh AK, Awasthi SK. Advancement of chimeric hybrid drugs to cure malaria infection: An overview with special emphasis on endoperoxide pharmacophores. Eur J Med Chem 2021; 219:113408. [PMID: 33989911 DOI: 10.1016/j.ejmech.2021.113408] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2020] [Revised: 03/19/2021] [Accepted: 03/19/2021] [Indexed: 12/27/2022]
Abstract
Emergence and spread of Plasmodium falciparum resistant to artemisinin-based combination therapy has led to a situation of haste in the scientific and pharmaceutical communities. Sincere efforts are redirected towards finding alternative chemotherapeutic agents that are capable of combating multidrug-resistant parasite strains. Extensive research yielded the concept of "Chimeric Bitherapy (CB)" which involves the linking of two molecules with individual pharmacological activity and exhibit dual mode of action into a single hybrid molecule. Current research in this field seems to endorse hybrid molecules as the next-generation antimalarial drugs and are more effective compared to the multi-component drugs because of the lower occurrence of drug-drug adverse effects. This review is an attempt to congregate complete survey on endoperoxide based hybrid antiplasmodial molecules that will give glimpse on the future directions for successful development and discovery of useful antimalarial hybrid drugs.
Collapse
Affiliation(s)
- Bhawana Sharma
- Chemical Biology Laboratory, Department of Chemistry, University of Delhi, Delhi 110007, India
| | - Preeti Singh
- Chemical Biology Laboratory, Department of Chemistry, University of Delhi, Delhi 110007, India
| | - Ashawani Kumar Singh
- Chemical Biology Laboratory, Department of Chemistry, University of Delhi, Delhi 110007, India
| | - Satish K Awasthi
- Chemical Biology Laboratory, Department of Chemistry, University of Delhi, Delhi 110007, India.
| |
Collapse
|
14
|
Uddin A, Chawla M, Irfan I, Mahajan S, Singh S, Abid M. Medicinal chemistry updates on quinoline- and endoperoxide-based hybrids with potent antimalarial activity. RSC Med Chem 2021; 12:24-42. [PMID: 34046596 PMCID: PMC8132992 DOI: 10.1039/d0md00244e] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2020] [Accepted: 10/19/2020] [Indexed: 02/01/2023] Open
Abstract
The resistance of conventional antimalarial drugs against the malarial parasite continues to pose a challenge to control the disease. The indiscriminate exploitation of the available antimalarials has resulted in increasing treatment failures, which urges on the search for novel lead molecules. Artemisinin-based combination therapy (ACT) is the current WHO-recommended first-line treatment for the majority of malaria cases. Hybrid molecules offer a newer strategy for the development of next-generation antimalarial drugs. These comprise molecules, each with an individual pharmacological activity, linked together into a single hybrid molecule. This approach has been utilized by several research groups to develop molecules with potent antimalarial activity. In this review, we provide an overview of the pivotal roles of quinoline- and endoperoxide-based hybrids as inhibitors of the life-cycle progression of Plasmodium. Based on the exhaustive literature reports, we have collated the structural and functional analyses of quinoline- and endoperoxide-based hybrid molecules that show potency equal to or greater than those of the individual compounds, offering an effective therapeutics option for clinical use.
Collapse
Affiliation(s)
- Amad Uddin
- Medicinal Chemistry Laboratory, Department of Biosciences, Jamia Millia Islamia Jamia Nagar New Delhi-110025 India +91 8750295095
- Special Centre for Molecular Medicine, Jawaharlal Nehru University New Delhi-110067 India
| | - Meenal Chawla
- Medicinal Chemistry Laboratory, Department of Biosciences, Jamia Millia Islamia Jamia Nagar New Delhi-110025 India +91 8750295095
| | - Iram Irfan
- Medicinal Chemistry Laboratory, Department of Biosciences, Jamia Millia Islamia Jamia Nagar New Delhi-110025 India +91 8750295095
| | - Shubhra Mahajan
- Medicinal Chemistry Laboratory, Department of Biosciences, Jamia Millia Islamia Jamia Nagar New Delhi-110025 India +91 8750295095
| | - Shailja Singh
- Special Centre for Molecular Medicine, Jawaharlal Nehru University New Delhi-110067 India
| | - Mohammad Abid
- Medicinal Chemistry Laboratory, Department of Biosciences, Jamia Millia Islamia Jamia Nagar New Delhi-110025 India +91 8750295095
| |
Collapse
|
15
|
Patel OPS, Beteck RM, Legoabe LJ. Antimalarial application of quinones: A recent update. Eur J Med Chem 2020; 210:113084. [PMID: 33333397 DOI: 10.1016/j.ejmech.2020.113084] [Citation(s) in RCA: 46] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2020] [Revised: 11/27/2020] [Accepted: 12/01/2020] [Indexed: 12/28/2022]
Abstract
Atovaquone belongs to a naphthoquinone class of drugs and is used in combination with proguanil (Malarone) for the treatment of acute, uncomplicated malaria caused by Plasmodium falciparum (including chloroquine-resistant P. falciparum/P. vivax). Numerous quinone-derived compounds have attracted considerable attention in the last few decades due to their potential in antimalarial drug discovery. Several semi-synthetic derivatives of natural quinones, synthetic quinones (naphtho-/benzo-quinone, anthraquinones, thiazinoquinones), and quinone-based hybrids were explored for their in vitro and in vivo antimalarial activities. A careful literature survey revealed that this topic has not been compiled as a review article so far. Therefore, we herein summarise the recent discovery (the year 2009-2020) of quinone based antimalarial compounds in chronological order. This compilation would be very useful towards the exploration of novel quinone-derived compounds against malarial parasites with promising efficacy and lesser side effects.
Collapse
Affiliation(s)
- Om P S Patel
- Centre of Excellence for Pharmaceutical Sciences, North-West University, Private Bag X6001, Potchefstroom, 2520, South Africa.
| | - Richard M Beteck
- Centre of Excellence for Pharmaceutical Sciences, North-West University, Private Bag X6001, Potchefstroom, 2520, South Africa
| | - Lesetja J Legoabe
- Centre of Excellence for Pharmaceutical Sciences, North-West University, Private Bag X6001, Potchefstroom, 2520, South Africa.
| |
Collapse
|
16
|
Aratikatla E, Kalamuddin M, Malhotra P, Mohmmed A, Bhattacharya AK. Enantioselective Synthesis of γ-Phenyl-γ-amino Vinyl Phosphonates and Sulfones and Their Application to the Synthesis of Novel Highly Potent Antimalarials. ACS OMEGA 2020; 5:29025-29037. [PMID: 33225134 PMCID: PMC7675543 DOI: 10.1021/acsomega.0c03470] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 07/20/2020] [Accepted: 10/16/2020] [Indexed: 06/11/2023]
Abstract
Racemic and enantioselective syntheses of γ-phenyl-γ-amino vinyl phosphonates and sulfones have been achieved using Horner-Wadsworth-Emmons olefination of trityl protected α-phenyl-α-amino aldehydes with tetraethyl methylenediphosphonate and diethyl ((phenylsulfonyl)methyl)phosphonate, respectively, without any racemization. The present strategy has also been successfully applied to the synthesis of peptidyl vinyl phosphonate and peptidyl vinyl sulfone derivatives as potential cysteine protease inhibitors of Chagas disease, K11002, with 100% de. The developed synthetic protocol was further utilized to synthesize hybrid molecules consisting of artemisinin as an inhibitor of major cysteine protease falcipain-2 present in the food vacuole of the malarial parasite. The synthesized artemisinin-dipeptidyl vinyl sulfone hybrid compounds showed effective in vitro inhibition of falcipain-2 and potent parasiticidal efficacies against Plasmodium falciparum in nanomolar ranges. Overall, the developed synthetic protocol could be effectively utilized to design cysteine protease inhibitors not only as novel antimalarial compounds but also to be involved in other life-threatening diseases.
Collapse
Affiliation(s)
- Eswar
K. Aratikatla
- Division
of Organic Chemistry, CSIR-National Chemical
Laboratory (CSIR-NCL), Dr. Homi Bhabha Road, Pune 411 008, India
- Academy
of Scientific and Innovative Research (AcSIR), CSIR-NCL, Pune 411 008, India
| | - Md Kalamuddin
- International
Centre for Genetic Engineering & Biotechnology (ICGEB) Aruna Asif
Ali Marg, New Delhi 100 067, India
| | - Pawan Malhotra
- International
Centre for Genetic Engineering & Biotechnology (ICGEB) Aruna Asif
Ali Marg, New Delhi 100 067, India
| | - Asif Mohmmed
- International
Centre for Genetic Engineering & Biotechnology (ICGEB) Aruna Asif
Ali Marg, New Delhi 100 067, India
| | - Asish K. Bhattacharya
- Division
of Organic Chemistry, CSIR-National Chemical
Laboratory (CSIR-NCL), Dr. Homi Bhabha Road, Pune 411 008, India
- Academy
of Scientific and Innovative Research (AcSIR), CSIR-NCL, Pune 411 008, India
| |
Collapse
|
17
|
Burns AL, Sleebs BE, Siddiqui G, De Paoli AE, Anderson D, Liffner B, Harvey R, Beeson JG, Creek DJ, Goodman CD, McFadden GI, Wilson DW. Retargeting azithromycin analogues to have dual-modality antimalarial activity. BMC Biol 2020; 18:133. [PMID: 32993629 PMCID: PMC7526119 DOI: 10.1186/s12915-020-00859-4] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2020] [Accepted: 08/28/2020] [Indexed: 11/22/2022] Open
Abstract
BACKGROUND Resistance to front-line antimalarials (artemisinin combination therapies) is spreading, and development of new drug treatment strategies to rapidly kill Plasmodium spp. malaria parasites is urgently needed. Azithromycin is a clinically used macrolide antibiotic proposed as a partner drug for combination therapy in malaria, which has also been tested as monotherapy. However, its slow-killing 'delayed-death' activity against the parasite's apicoplast organelle and suboptimal activity as monotherapy limit its application as a potential malaria treatment. Here, we explore a panel of azithromycin analogues and demonstrate that chemical modifications can be used to greatly improve the speed and potency of antimalarial action. RESULTS Investigation of 84 azithromycin analogues revealed nanomolar quick-killing potency directed against the very earliest stage of parasite development within red blood cells. Indeed, the best analogue exhibited 1600-fold higher potency than azithromycin with less than 48 hrs treatment in vitro. Analogues were effective against zoonotic Plasmodium knowlesi malaria parasites and against both multi-drug and artemisinin-resistant Plasmodium falciparum lines. Metabolomic profiles of azithromycin analogue-treated parasites suggested activity in the parasite food vacuole and mitochondria were disrupted. Moreover, unlike the food vacuole-targeting drug chloroquine, azithromycin and analogues were active across blood-stage development, including merozoite invasion, suggesting that these macrolides have a multi-factorial mechanism of quick-killing activity. The positioning of functional groups added to azithromycin and its quick-killing analogues altered their activity against bacterial-like ribosomes but had minimal change on 'quick-killing' activity. Apicoplast minus parasites remained susceptible to both azithromycin and its analogues, further demonstrating that quick-killing is independent of apicoplast-targeting, delayed-death activity. CONCLUSION We show that azithromycin and analogues can rapidly kill malaria parasite asexual blood stages via a fast action mechanism. Development of azithromycin and analogues as antimalarials offers the possibility of targeting parasites through both a quick-killing and delayed-death mechanism of action in a single, multifactorial chemotype.
Collapse
Affiliation(s)
- Amy L Burns
- Research Centre for Infectious Diseases, School of Biological Sciences, The University of Adelaide, Adelaide, 5005, Australia
| | - Brad E Sleebs
- Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, 3050, Australia
- Department of Medical Biology, University of Melbourne, Melbourne, Victoria, 3050, Australia
| | - Ghizal Siddiqui
- Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Victoria, 3052, Australia
| | - Amanda E De Paoli
- Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Victoria, 3052, Australia
| | - Dovile Anderson
- Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Victoria, 3052, Australia
| | - Benjamin Liffner
- Research Centre for Infectious Diseases, School of Biological Sciences, The University of Adelaide, Adelaide, 5005, Australia
| | - Richard Harvey
- Research Centre for Infectious Diseases, School of Biological Sciences, The University of Adelaide, Adelaide, 5005, Australia
| | - James G Beeson
- Burnet Institute, Melbourne, Victoria, 3004, Australia
- Department of Medicine, University of Melbourne, Melbourne, Australia
- Central Clinical School and Department of Microbiology, Monash University, Melbourne, Australia
| | - Darren J Creek
- Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Victoria, 3052, Australia
| | - Christopher D Goodman
- School of Biosciences, University of Melbourne, Melbourne, Victoria, 3010, Australia
| | - Geoffrey I McFadden
- School of Biosciences, University of Melbourne, Melbourne, Victoria, 3010, Australia
| | - Danny W Wilson
- Research Centre for Infectious Diseases, School of Biological Sciences, The University of Adelaide, Adelaide, 5005, Australia.
- Burnet Institute, Melbourne, Victoria, 3004, Australia.
| |
Collapse
|
18
|
Abstract
As the world gets closer to eliminating malaria, the scientific community worldwide has begun to realize the importance of malaria transmission-blocking interventions. The onus of breaking the life cycle of the human malaria parasite Plasmodium falciparum predominantly rests upon transmission-blocking drugs because of emerging resistance to commonly used schizonticides and insecticides. This third part of our review series on malaria transmission-blocking entails transmission-blocking potential of preclinical transmission-blocking antimalarials and other non-malaria drugs/experimental compounds that are not in clinical or preclinical development for malaria but possess transmission-blocking potential. Collective analysis of the structure and the activity of these experimental compounds might pave the way toward generation of novel prototypes of next-generation transmission-blocking drugs.
Collapse
|
19
|
Joshi MC, Egan TJ. Quinoline Containing Side-chain Antimalarial Analogs: Recent Advances and Therapeutic Application. Curr Top Med Chem 2020; 20:617-697. [DOI: 10.2174/1568026620666200127141550] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2019] [Revised: 10/25/2019] [Accepted: 10/30/2019] [Indexed: 01/16/2023]
Abstract
The side-chains of quinoline antimalarial agents are the major concern of focus to build
novel and efficaciaous bioactive and clinical antimalarials. Bioative antimalarial analogs may play a
critical role in pH trapping in the food vacuole of RBC’s with the help of fragmented amino acid, thus
lead to β-hematin inhibition. Here, the authors tried to summarize a useful, comprehensive compilation
of side-chain modified ACQs along with their synthesis, biophysical and therapeutic applications etc.
of potent antiplasmodial agents and therefore, opening the door towards the potential clinical status.
Collapse
Affiliation(s)
- Mukesh C. Joshi
- Department of Chemistry, Motilal Nehru College, Benito Juarez Marg, South Campus, University of Delhi, New Delhi- 110021, India
| | - Timothy J. Egan
- Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa
| |
Collapse
|
20
|
Tibon NS, Ng CH, Cheong SL. Current progress in antimalarial pharmacotherapy and multi-target drug discovery. Eur J Med Chem 2019; 188:111983. [PMID: 31911292 DOI: 10.1016/j.ejmech.2019.111983] [Citation(s) in RCA: 34] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2019] [Revised: 12/09/2019] [Accepted: 12/16/2019] [Indexed: 12/13/2022]
Abstract
Discovery and development of antimalarial drugs have long been dominated by single-target therapy. Continuous effort has been made to explore and identify different targets in malaria parasite crucial for the malaria treatment. The single-target drug therapy was initially successful, but it was later supplanted by combination therapy with multiple drugs to overcome drug resistance. Emergence of resistant strains even against the combination therapy has warranted a review of current antimalarial pharmacotherapy. This has led to the development of the new concept of covalent biotherapy, in which two or more pharmacophores are chemically bound to produce hybrid antimalarial drugs with multi-target functionalities. Herein, the review initially details the current pharmacotherapy for malaria as well as the conventional and novel targets of importance identified in the malaria parasite. Then, the rationale of multi-targeted therapy for malaria, approaches taken to develop the multi-target antimalarial hybrids, and the examples of hybrid molecules are comprehensively enumerated and discussed.
Collapse
Affiliation(s)
- Natasha Stella Tibon
- Department of Pharmaceutical Chemistry, School of Pharmacy, International Medical University, No. 126, Jalan Jalil Perkasa 19, Bukit Jalil, 57000, Kuala Lumpur, Malaysia
| | - Chew Hee Ng
- Department of Pharmaceutical Chemistry, School of Pharmacy, International Medical University, No. 126, Jalan Jalil Perkasa 19, Bukit Jalil, 57000, Kuala Lumpur, Malaysia.
| | - Siew Lee Cheong
- Department of Pharmaceutical Chemistry, School of Pharmacy, International Medical University, No. 126, Jalan Jalil Perkasa 19, Bukit Jalil, 57000, Kuala Lumpur, Malaysia.
| |
Collapse
|
21
|
Vieira RP, Santos VC, Ferreira RS. Structure-based Approaches Targeting Parasite Cysteine Proteases. Curr Med Chem 2019; 26:4435-4453. [PMID: 28799498 DOI: 10.2174/0929867324666170810165302] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2017] [Revised: 07/18/2017] [Accepted: 07/18/2017] [Indexed: 12/17/2022]
Abstract
Cysteine proteases are essential hydrolytic enzymes present in the majority of organisms, including viruses and unicellular parasites. Despite the high sequence identity displayed among these proteins, specific structural features across different species grant distinct functions to these biomolecules, frequently related to pathological conditions. Consequently, their relevance as promising targets for potential specific inhibitors has been highlighted and occasionally validated in recent decades. In this review, we discuss the recent outcomes of structure-based campaigns aiming the discovery of new inhibitor prototypes against cruzain and falcipain, as alternative therapeutic tools for Chagas disease and malaria treatments, respectively. Computational and synthetic approaches have been combined on hit optimization strategies and are also discussed herein. These rationales are extended to additional tropical infectious and neglected pathologies, such as schistosomiasis, leishmaniasis and babesiosis, and also to Alzheimer's Disease, a widespread neurodegenerative disease poorly managed by currently available drugs and recently linked to particular physiopathological roles of human cysteine proteases.
Collapse
Affiliation(s)
- Rafael Pinto Vieira
- Departamento de Bioquimica e Imunologia, Instituto de Ciencias Biologicas, Universidade Federal de Minas Gerais, 31270-901 Belo Horizonte, MG, Brazil.,CAPES Foundation, Ministry of Education of Brazil, 70040-020 Brasília, DF, Brazil
| | - Viviane Corrêa Santos
- Departamento de Bioquimica e Imunologia, Instituto de Ciencias Biologicas, Universidade Federal de Minas Gerais, 31270-901 Belo Horizonte, MG, Brazil
| | - Rafaela Salgado Ferreira
- Departamento de Bioquimica e Imunologia, Instituto de Ciencias Biologicas, Universidade Federal de Minas Gerais, 31270-901 Belo Horizonte, MG, Brazil
| |
Collapse
|
22
|
Artemisinin and its derivatives; ancient tradition inspiring the latest therapeutic approaches against malaria. Future Med Chem 2019; 11:1443-1459. [PMID: 31298579 DOI: 10.4155/fmc-2018-0337] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Artemisinin (ART) is an endoperoxide sesquiterpene lactone, commonly used in the treatment of malaria. Although it was isolated from Artemisia annua L., a plant widely applied in Chinese Traditional Medicine, its mechanism of action remains uncertain and its clinical use is still limited due to its low solubility, its poor bioavailability and short in vivo half-life. Over time, several studies have been aimed towards the discovery of potent ART derivatives that could overcome clinical drawbacks. In this review, we focus on the multifaced aspects of ART and on the efforts spent to improve its pharmacological profile that so far culminated in the discovery of more effective drugs. Lastly, we outline the new perspectives in the ART-derivatives scenario.
Collapse
|
23
|
Paloque L, Witkowski B, Lelièvre J, Ouji M, Ben Haddou T, Ariey F, Robert A, Augereau JM, Ménard D, Meunier B, Benoit-Vical F. Endoperoxide-based compounds: cross-resistance with artemisinins and selection of a Plasmodium falciparum lineage with a K13 non-synonymous polymorphism. J Antimicrob Chemother 2019; 73:395-403. [PMID: 29177421 DOI: 10.1093/jac/dkx412] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2017] [Accepted: 10/09/2017] [Indexed: 11/12/2022] Open
Abstract
Background Owing to the emergence of multiresistant Plasmodium falciparum parasites in Southeast Asia, along with the impressive decrease in the efficacy of the endoperoxide compound artemisinin and of artemisinin-based combination therapies, the development of novel antimalarial drugs or combinations is required. Although several antiplasmodial molecules, such as endoperoxide-based compounds, are in advanced research or development, we do not know whether resistance to artemisinin derivatives might impact the efficacy of these new compounds. Objectives To address this issue, the antiplasmodial efficacy of trioxaquines, hybrid endoperoxide-based molecules, was explored, along with their ability to select in vitro resistant parasites under discontinuous and dose-escalating drug pressure. Methods The in vitro susceptibilities of artemisinin- and trioxaquine-resistant laboratory strains and recent Cambodian field isolates were evaluated by different phenotypic and genotypic assays. Results Trioxaquines tested presented strong cross-resistance with artemisinin both in the artemisinin-resistant laboratory F32-ART5 line and in Cambodian field isolates. Trioxaquine drug pressure over 4 years led to the in vitro selection of the F32-DU line, which is resistant to trioxaquine and artemisinin, similar to the F32-ART lineage. F32-DU whole genome sequencing (WGS) revealed that resistance to trioxaquine was associated with the same non-synonymous mutation in the propeller domain of the K13 protein (M476I) that was found in the F32-ART lineage. Conclusions These worrisome results indicate the risk of cross-resistance between artemisinins and endoperoxide-based antiplasmodial drugs in the development of the K13 mutant parasites and question the usefulness of these molecules in the future therapeutic arsenal.
Collapse
Affiliation(s)
- Lucie Paloque
- CNRS; LCC (Laboratoire de Chimie de Coordination), 205 route de Narbonne, F-31077 Toulouse, France.,Université de Toulouse; UPS, INPT; LCC, F-31077 Toulouse, France
| | - Benoit Witkowski
- CNRS; LCC (Laboratoire de Chimie de Coordination), 205 route de Narbonne, F-31077 Toulouse, France.,Université de Toulouse; UPS, INPT; LCC, F-31077 Toulouse, France.,Malaria Molecular Epidemiology Unit, Institut Pasteur du Cambodge, Phnom Penh, Cambodia
| | - Joël Lelièvre
- CNRS; LCC (Laboratoire de Chimie de Coordination), 205 route de Narbonne, F-31077 Toulouse, France.,Université de Toulouse; UPS, INPT; LCC, F-31077 Toulouse, France
| | - Manel Ouji
- CNRS; LCC (Laboratoire de Chimie de Coordination), 205 route de Narbonne, F-31077 Toulouse, France.,Université de Toulouse; UPS, INPT; LCC, F-31077 Toulouse, France
| | - Tanila Ben Haddou
- CNRS; LCC (Laboratoire de Chimie de Coordination), 205 route de Narbonne, F-31077 Toulouse, France.,Université de Toulouse; UPS, INPT; LCC, F-31077 Toulouse, France
| | - Frédéric Ariey
- INSERM 1016, Institut Cochin, Université Paris Descartes et Service de Parasitologie-Mycologie Hôpital Cochin, Paris
| | - Anne Robert
- CNRS; LCC (Laboratoire de Chimie de Coordination), 205 route de Narbonne, F-31077 Toulouse, France.,Université de Toulouse; UPS, INPT; LCC, F-31077 Toulouse, France
| | - Jean-Michel Augereau
- CNRS; LCC (Laboratoire de Chimie de Coordination), 205 route de Narbonne, F-31077 Toulouse, France.,Université de Toulouse; UPS, INPT; LCC, F-31077 Toulouse, France
| | - Didier Ménard
- Malaria Molecular Epidemiology Unit, Institut Pasteur du Cambodge, Phnom Penh, Cambodia
| | - Bernard Meunier
- CNRS; LCC (Laboratoire de Chimie de Coordination), 205 route de Narbonne, F-31077 Toulouse, France.,Université de Toulouse; UPS, INPT; LCC, F-31077 Toulouse, France
| | - Françoise Benoit-Vical
- CNRS; LCC (Laboratoire de Chimie de Coordination), 205 route de Narbonne, F-31077 Toulouse, France.,Université de Toulouse; UPS, INPT; LCC, F-31077 Toulouse, France
| |
Collapse
|
24
|
Choudhary S, Singh PK, Verma H, Singh H, Silakari O. Success stories of natural product-based hybrid molecules for multi-factorial diseases. Eur J Med Chem 2018; 151:62-97. [PMID: 29605809 DOI: 10.1016/j.ejmech.2018.03.057] [Citation(s) in RCA: 60] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2018] [Revised: 03/19/2018] [Accepted: 03/20/2018] [Indexed: 12/18/2022]
Abstract
Complex diseases comprises of highly complicated etiology resulting in limited applicability of conventional targeted therapies. Consequently, conventional medicinal compounds suffer major failure when used for such disease conditions. Additionally, development of multidrug resistance (MDR), adverse drug reactions and clinical specificity of single targeted drug therapy has increased thrust for novel drug therapy. In this rapidly evolving era, natural product-based discovery of hybrid molecules or multi-targeted drug therapies have shown promising results and are trending now a days. Historically, nature has blessed human with different sources viz. plant, animal, microbial, marine and ethnopharmaceutical sources which has given a wide variety of medicinally active compounds. These compounds from natural origin are always choice of interest of medicinal chemists because of their minimum side effects. Hybrid molecules synthesized by fusing or conjugating different active molecules obtained from these sources are reported to synergistically block different pathways which contribute in the pathogenesis of complex diseases. This review strives to encompass all natural product-derived hybrid molecules which act as multi-targeting agents striking various targets involved in different pathways of complex diseased conditions reported in literature.
Collapse
Affiliation(s)
- Shalki Choudhary
- Molecular Modelling Lab (MML), Department of Pharmaceutical Sciences and Drug research, Punjabi University, Patiala, Punjab, 147002, India
| | - Pankaj Kumar Singh
- Molecular Modelling Lab (MML), Department of Pharmaceutical Sciences and Drug research, Punjabi University, Patiala, Punjab, 147002, India
| | - Himanshu Verma
- Molecular Modelling Lab (MML), Department of Pharmaceutical Sciences and Drug research, Punjabi University, Patiala, Punjab, 147002, India
| | | | - Om Silakari
- Molecular Modelling Lab (MML), Department of Pharmaceutical Sciences and Drug research, Punjabi University, Patiala, Punjab, 147002, India.
| |
Collapse
|
25
|
Duffey M, Sanchez CP, Lanzer M. Profiling of the anti-malarial drug candidate SC83288 against artemisinins in Plasmodium falciparum. Malar J 2018; 17:121. [PMID: 29558913 PMCID: PMC5861637 DOI: 10.1186/s12936-018-2279-4] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2017] [Accepted: 03/15/2018] [Indexed: 12/29/2022] Open
Abstract
Background The increased resistance of the human malaria parasite Plasmodium falciparum to currently employed drugs creates an urgent call for novel anti-malarial drugs. Particularly, efforts should be devoted to developing fast-acting anti-malarial compounds in case clinical resistance increases to the first-line artemisinin-based combination therapy. SC83288, an amicarbalide derivative, is a clinical development candidate for the treatment of severe malaria. SC83288 is fast-acting and able to clear P. falciparum parasites at low nanomolar concentrations in vitro, as well as in a humanized SCID mouse model system in vivo. In this study, the antiplasmodial activity of SC83288 against artemisinins was profiled in order to assess its potential to replace, or be combined with, artemisinin derivatives. Results Based on growth inhibition and ring survival assays, no cross-resistance was observed between artemisinins and SC83288, using parasite lines that were resistant to either one of these drugs. In addition, no synergistic or antagonistic interaction was observed between the two drugs. This study further confirmed that SC83288 is a fast acting drug in several independent assays. Combinations of SC83288 and artesunate maintained the rapid parasite killing activities of both components. Conclusion The results obtained in this study are consistent with artemisinins and SC83288 having distinct modes of action and different mechanisms of resistance. This study further supports efforts to continue the clinical development of SC83288 against severe malaria as an alternative to artemisinins in areas critically affected by artemisinin-resistance. Considering its fast antiplasmodial activity, SC83288 could be combined with a slow-acting anti-malarial drug.
Collapse
Affiliation(s)
- Maëlle Duffey
- Department of Infectious Diseases, Parasitology, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 324, 69120, Heidelberg, Germany.,German Center for Infection Research (DZIF), Partner Site Heidelberg, 69120, Heidelberg, Germany
| | - Cecilia P Sanchez
- Department of Infectious Diseases, Parasitology, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 324, 69120, Heidelberg, Germany.,German Center for Infection Research (DZIF), Partner Site Heidelberg, 69120, Heidelberg, Germany
| | - Michael Lanzer
- Department of Infectious Diseases, Parasitology, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 324, 69120, Heidelberg, Germany. .,German Center for Infection Research (DZIF), Partner Site Heidelberg, 69120, Heidelberg, Germany.
| |
Collapse
|
26
|
Gouveia MJ, Brindley PJ, Gärtner F, Costa JMCD, Vale N. Drug Repurposing for Schistosomiasis: Combinations of Drugs or Biomolecules. Pharmaceuticals (Basel) 2018; 11:E15. [PMID: 29401734 PMCID: PMC5874711 DOI: 10.3390/ph11010015] [Citation(s) in RCA: 38] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2017] [Revised: 01/19/2018] [Accepted: 01/31/2018] [Indexed: 12/17/2022] Open
Abstract
Schistosomiasis is a major neglected tropical disease. Control of schistosomiasis currently relies on a single drug, praziquantel, and despite its efficacy against the all schistosome species that parasitize humans, it displays some problematic drawbacks and alone is ineffective in counteracting adverse pathologies associated with infection. Moreover, due to the development of the potential emergence of PZQ-resistant strains, the search for additional or alternative antischistosomal drugs have become a public health priority. The current drug discovery for schistosomiasis has been slow and uninspiring. By contrast, repurposing of existing approved drugs may offer a safe, rapid and cost-effective alternative. Combined treatment with PZQ and other drugs with different mode of action, i.e., antimalarials, shows promise results. In addition, a combination of anthelminthic drugs with antioxidant might be advantageous for modulating oxidative processes associated with schistosomiasis. Herein, we review studies dealing with combination therapies that involve PZQ and other anthelminthic drugs and/or antioxidant agents in treatment of schistosomiasis. Whereas PZQ combined with antioxidant agents might or might not interfere with anthelminthic efficacy, combinations may nonetheless ameliorate tissue damage and infection-associated complications. In fact, alone or combine with other drugs, antioxidants might be a valuable adjuvant to reduce morbidity and mortality of schistosomiasis. Therefore, attempting new combinations of anthelmintic drugs with other biomolecules such as antioxidants provides new avenues for discovery of alternatives to PZQ.
Collapse
Affiliation(s)
- Maria João Gouveia
- UCBIO/REQUIMTE, Laboratory of Pharmacology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, Rua de Jorge Viterbo, 228, 4050-313 Porto, Portugal.
- Center for the Study of Animal Science, ICETA, University of Porto, Praça Gomes Teixeira, Apartado 55142, 4031-401 Porto, Portugal.
- Department of Molecular Pathology and Immunology, Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, Rua de Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal.
| | - Paul J Brindley
- Department of Microbiology, Immunology & Tropical Medicine, and Research Center for Neglected Diseases of Poverty, School of Medicine & Health Sciences, George Washington University, Washington, DC 20037, USA.
| | - Fátima Gärtner
- Department of Molecular Pathology and Immunology, Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, Rua de Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal.
- Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Rua Júlio Amaral de Carvalho, 45, 4200-135 Porto, Portugal.
- Institute of Investigation and Innovation in Health (i3s), Rua Alfredo Allen, 4200-135 Porto, Portugal.
| | - José M Correia da Costa
- Center for the Study of Animal Science, ICETA, University of Porto, Praça Gomes Teixeira, Apartado 55142, 4031-401 Porto, Portugal.
- Department of Infectious Diseases, INSA-National Health Institute Dr. Ricardo Jorge, Rua Alexandre Herculano 321, 4000-055 Porto, Portugal.
| | - Nuno Vale
- UCBIO/REQUIMTE, Laboratory of Pharmacology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, Rua de Jorge Viterbo, 228, 4050-313 Porto, Portugal.
| |
Collapse
|
27
|
Poonam, Gupta Y, Gupta N, Singh S, Wu L, Chhikara BS, Rawat M, Rathi B. Multistage inhibitors of the malaria parasite: Emerging hope for chemoprotection and malaria eradication. Med Res Rev 2018; 38:1511-1535. [DOI: 10.1002/med.21486] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2017] [Revised: 12/09/2017] [Accepted: 12/26/2017] [Indexed: 12/13/2022]
Affiliation(s)
- Poonam
- Department of Chemistry; Miranda House, University of Delhi; India
| | - Yash Gupta
- National Institute of Malaria Research (ICMR); New Delhi India
| | - Nikesh Gupta
- Special Centre for Nanosciences; Jawaharlal Nehru University; New Delhi India
| | - Snigdha Singh
- Laboratory for Translational Chemistry and Drug Discovery, Department of Chemistry; Hansraj College University Enclave, University of Delhi; Delhi India
| | - Lidong Wu
- Department of Chemistry; Massachusetts Institute of Technology; Cambridge MA USA
- Key Laboratory of Control of Quality and Safety for Aquatic Products; Ministry of Agriculture, Chinese Academy of Fishery Sciences; Beijing China
| | | | - Manmeet Rawat
- Department of Internal Medicine; University of New Mexico School of Medicine; Albuquerque NM USA
| | - Brijesh Rathi
- Laboratory for Translational Chemistry and Drug Discovery, Department of Chemistry; Hansraj College University Enclave, University of Delhi; Delhi India
- Department of Chemistry; Massachusetts Institute of Technology; Cambridge MA USA
| |
Collapse
|
28
|
Moreno-Sabater A, Pérignon JL, Mazier D, Lavazec C, Soulard V. Humanized mouse models infected with human Plasmodium species for antimalarial drug discovery. Expert Opin Drug Discov 2017; 13:131-140. [DOI: 10.1080/17460441.2018.1410136] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Affiliation(s)
- Alicia Moreno-Sabater
- UPMC Faculte de Medecine - INSERM U1135, CNRS ERL 8255, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, Île-de-France France
- Assistance Publique - Hopitaux de Paris - Hôpitaux Universitaires Paris-Est - Site Saint-Antoine, Paris, Île-de-France France
| | | | - Dominique Mazier
- UPMC Faculte de Medecine - INSERM U1135, CNRS ERL 8255, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, Île-de-France France
| | - Catherine Lavazec
- Institut Cochin – INSERM U1016, Paris, Île-de-France France
- CNRS - UMR8104, Paris, France
- Universite Paris Descartes, Paris, Île-de-France France
| | - Valerie Soulard
- UPMC Faculte de Medecine - INSERM U1135, CNRS ERL 8255, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, Île-de-France France
| |
Collapse
|
29
|
Hu YQ, Gao C, Zhang S, Xu L, Xu Z, Feng LS, Wu X, Zhao F. Quinoline hybrids and their antiplasmodial and antimalarial activities. Eur J Med Chem 2017; 139:22-47. [DOI: 10.1016/j.ejmech.2017.07.061] [Citation(s) in RCA: 203] [Impact Index Per Article: 29.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2017] [Revised: 07/24/2017] [Accepted: 07/24/2017] [Indexed: 11/30/2022]
|
30
|
Odhiambo OC, Wamakima HN, Magoma GN, Kirira PG, Malala BJ, Kimani FT, Muregi FW. Efficacy and safety evaluation of a novel trioxaquine in the management of cerebral malaria in a mouse model. Malar J 2017; 16:268. [PMID: 28673299 PMCID: PMC5496145 DOI: 10.1186/s12936-017-1917-6] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2016] [Accepted: 06/27/2017] [Indexed: 11/22/2022] Open
Abstract
Background The emergence of multidrug-resistant strains of Plasmodium falciparum poses a great threat of increased fatalities in cases of cerebral and other forms of severe malaria infections in which parenteral artesunate monotherapy is the current drug of choice. The study aimed to investigate in a mouse model of human cerebral malaria whether a trioxaquine chemically synthesized by covalent linking of a 4,7-dichloroquinoline pharmacophore to artesunate through a recent drug development approach termed ‘covalent bitherapy’ could improve the curative outcomes in cerebral malaria infections. Methods Human cerebral malaria rodent model, the C57BL/6 male mice were infected intraperitoneally (ip) with Plasmodium berghei ANKA and intravenously (iv) treated with the trioxaquine from day 8 post-infection (pi) at 12.5 and 25 mg/kg, respectively, twice a day for 3 days. Treatments with the trioxaquine precursors (artesunate and 4,7-dichloroquine), and quinine were also included as controls. In vivo safety evaluation for the trioxaquine was done according to Organization for Economic Co-operation and Development (OECD) guidelines 423, where female Swiss albino mice were orally administered with either 300 or 2000 mg/kg of the trioxaquine and monitored for signs of severity, and or mortality for 14 days post-treatment. Results The trioxaquine showed a potent and a rapid antiplasmodial activity with 80% parasite clearance in the first 24 h for the two dosages used. Long-term parasitaemia monitoring showed a total parasite clearance as the treated mice survived beyond 60 days post-treatment, with no recrudescence observed. Artesunate treated mice showed recrudescence 8 days post-treatment, with all mice in this group succumbing to the infection. Also, 4,7-dichloroquinoline and quinine did not show any significant parasitaemia suppression in the first 24 h post-treatment, with the animals succumbing to the infection. Conclusion Covalent bitherapy proves to be a viable source of urgently needed new anti-malarials for management of cerebral malaria, and this polypharmacology approach could be a potential strategy to protect artesunate from parasite resistance and in potentially improving clinical outcomes in severe forms of malaria infections.
Collapse
Affiliation(s)
- Onyango C Odhiambo
- Department of Biochemistry, Jomo Kenyatta University of Agriculture and Technology, P.O. Box 62000, Nairobi, Kenya
| | - Hannah N Wamakima
- Department of Pharmaceutical Sciences, Mount Kenya University, P.O. Box 342-01000, Thika, Kenya
| | - Gabriel N Magoma
- Department of Biochemistry, Jomo Kenyatta University of Agriculture and Technology, P.O. Box 62000, Nairobi, Kenya
| | - Peter G Kirira
- Department of Physical Sciences, Mount Kenya University, P.O. Box 342-01000, Thika, Kenya
| | - Bonface J Malala
- Department of Biological Sciences, Mount Kenya University, P.O. Box 342-01000, Thika, Kenya
| | - Francis T Kimani
- Centre for Biotechnology Research and Development, Kenya Medical Research Institute (KEMRI), P.O. Box 54840, Nairobi, Kenya
| | - Francis W Muregi
- Department of Biological Sciences, Mount Kenya University, P.O. Box 342-01000, Thika, Kenya.
| |
Collapse
|
31
|
Are Antimalarial Hybrid Molecules a Close Reality or a Distant Dream? Antimicrob Agents Chemother 2017; 61:AAC.00249-17. [PMID: 28289029 DOI: 10.1128/aac.00249-17] [Citation(s) in RCA: 43] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
Emergence of drug-resistant Plasmodium falciparum strains has led to a situation of haste in the scientific and pharmaceutical communities. Hence, all their efforts are redirected toward finding alternative chemotherapeutic agents that are capable of combating multidrug-resistant parasite strains. In light of this situation, scientists have come up with the concept of hybridization of two or more active pharmacophores into a single chemical entity, resulting in "antimalarial hybrids." The approach has been applied widely for generation of lead compounds against deadly diseases such as cancer and AIDS, with a proven potential for use as novel drugs, but is comparatively new in the sphere of antimalarial drug discovery. A sudden surge has been evidenced in the number of studies on the design and synthesis of hybrids for treating malaria and may be regarded as proof of their potential advantages over artemisinin-based combination therapy (ACT). However, it is evident from recent studies that most of the potential advantages of antimalarial hybrids, such as lower toxicity, better pharmacokinetics, and easier formulation, have yet to be realized. A number of questions left unaddressed at present need to be answered before this approach can progress to the late stages of clinical development and prove their worth in the clinic. To the best of our knowledge, this compilation is the first attempt to shed light on the shortcomings that are surfacing as more and more studies on molecular hybridization of the active pharmacophores of known antimalarials are being published.
Collapse
|
32
|
Parhizgar AR, Tahghighi A. Introducing New Antimalarial Analogues of Chloroquine and Amodiaquine: A Narrative Review. IRANIAN JOURNAL OF MEDICAL SCIENCES 2017; 42:115-128. [PMID: 28360437 PMCID: PMC5366359] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/18/2016] [Revised: 05/02/2016] [Accepted: 06/05/2016] [Indexed: 11/03/2022]
Abstract
Antimalarial drugs with the 4-aminoquinoline scaffold such as the important drugs, chloroquine (CQ) and amodiaquine (AQ), have been used to prevent and treat malaria for many years. The importance of these drugs is related to their simple usage, high efficacy, affordability, and cost-effectiveness of their synthesis. In recent years, with the spread of parasite resistance to CQ and cross-resistance to its other analogues have decreased their consumption in many geographical areas. On the other hand, AQ is an effective antimalarial drug which its usage has been restricted due to hepatic and hematological toxicities. The significance of the quinoline ring at quinoline-based antimalarial drugs has prompted research centers and pharmaceutical companies to focus on the design and synthesis of new analogues of these drugs, especially CQ and AQ analogues. Accordingly, various derivatives have been synthesized and evaluated in vitro and in vivo against the resistant strains of the malaria parasite to solve the problem of drug resistance. Also, the pharmacokinetic properties of these compounds have been evaluated to augment their efficacy and diminish their toxicity. Some of these analogues are currently in clinical and preclinical development. Consequently, the recent researches showed yet 4-aminoquinoline scaffold is active moiety in new compounds with antiplasmodial activity. Hence, the aim of this review article is to introduce of the novel synthetic analogues of CQ and AQ, which may constitute the next generation of antimalarial drugs with the 4-aminoquinoline scaffold.
Collapse
Affiliation(s)
- Arezoo Rafiee Parhizgar
- Malaria and Vector Research Group (MVRG), Biotechnology Research Center (BRC), Pasteur Institute of Iran, Tehran, Iran
- Department of Medicinal Chemistry, Pharmaceutical Sciences Branch, Islamic Azad University, Tehran, Iran
| | - Azar Tahghighi
- Malaria and Vector Research Group (MVRG), Biotechnology Research Center (BRC), Pasteur Institute of Iran, Tehran, Iran
| |
Collapse
|
33
|
Computer-Aided Drug Discovery from Marine Compounds: Identification of the Three-Dimensional Structural Features Responsible for Antimalarial Activity. PROGRESS IN MOLECULAR AND SUBCELLULAR BIOLOGY 2017. [PMID: 28238037 DOI: 10.1007/978-3-319-51284-6_4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register]
Abstract
An integrated computational approach, based on molecular dynamics/mechanics, semi-empirical, and DFT calculations as well as dynamic docking studies, has been employed to gain insight into the mechanism of action of new antimalarial agents characterized by the scaffold of the marine compounds plakortin and aplidinone. The results of this approach show that these molecules, after interaction with Fe(II), likely coming from the heme molecule, give rise to the formation of radical species, that should represent the toxic intermediates responsible for subsequent reactions leading to plasmodium death. The three-dimensional structural requirements necessary for the activity of these new classes of antimalarial agents have been identified and discussed throughout the chapter.
Collapse
|
34
|
Pegoraro S, Duffey M, Otto TD, Wang Y, Rösemann R, Baumgartner R, Fehler SK, Lucantoni L, Avery VM, Moreno-Sabater A, Mazier D, Vial HJ, Strobl S, Sanchez CP, Lanzer M. SC83288 is a clinical development candidate for the treatment of severe malaria. Nat Commun 2017; 8:14193. [PMID: 28139658 PMCID: PMC5290327 DOI: 10.1038/ncomms14193] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2016] [Accepted: 12/07/2016] [Indexed: 01/11/2023] Open
Abstract
Severe malaria is a life-threatening complication of an infection with the protozoan parasite Plasmodium falciparum, which requires immediate treatment. Safety and efficacy concerns with currently used drugs accentuate the need for new chemotherapeutic options against severe malaria. Here we describe a medicinal chemistry program starting from amicarbalide that led to two compounds with optimized pharmacological and antiparasitic properties. SC81458 and the clinical development candidate, SC83288, are fast-acting compounds that can cure a P. falciparum infection in a humanized NOD/SCID mouse model system. Detailed preclinical pharmacokinetic and toxicological studies reveal no observable drawbacks. Ultra-deep sequencing of resistant parasites identifies the sarco/endoplasmic reticulum Ca2+ transporting PfATP6 as a putative determinant of resistance to SC81458 and SC83288. Features, such as fast parasite killing, good safety margin, a potentially novel mode of action and a distinct chemotype support the clinical development of SC83288, as an intravenous application for the treatment of severe malaria.
Collapse
Affiliation(s)
| | - Maëlle Duffey
- Department of Infectious Diseases, Parasitology, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 324, 69120 Heidelberg, Germany
- German Center for Infection Research (DZIF), partner site Heidelberg, 69120 Heidelberg, Germany
| | - Thomas D Otto
- Parasite Genomics, Wellcome Trust Sanger Institute, Wellcome Genome Campus, Hinxton CB10 1SA, UK
| | - Yulin Wang
- Department of Infectious Diseases, Parasitology, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 324, 69120 Heidelberg, Germany
- German Center for Infection Research (DZIF), partner site Heidelberg, 69120 Heidelberg, Germany
| | - Roman Rösemann
- 4SC Discovery GmbH, Am Klopferspitz 19a, 82152 Martinsried, Germany
| | | | - Stefanie K Fehler
- 4SC AG, Am Klopferspitz 19a, 82152 Martinsried, Germany
- Department of Infectious Diseases, Parasitology, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 324, 69120 Heidelberg, Germany
- German Center for Infection Research (DZIF), partner site Heidelberg, 69120 Heidelberg, Germany
| | - Leonardo Lucantoni
- Eskitis Institute for Drug Discovery, Griffith University, Don Young, Nathan Queensland 4111, Australia
| | - Vicky M Avery
- Eskitis Institute for Drug Discovery, Griffith University, Don Young, Nathan Queensland 4111, Australia
| | - Alicia Moreno-Sabater
- Sorbonne Universités, UPMC Univ Paris 06, INSERM U1135, CNRS ERL 8255, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), 91 Bd de l'hôpital, F-75013 Paris, France
- AP-HP, Hôpital St Antoine, Service de Parasitologie-Mycologie, F-75012 Paris, France
| | - Dominique Mazier
- Sorbonne Universités, UPMC Univ Paris 06, INSERM U1135, CNRS ERL 8255, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), 91 Bd de l'hôpital, F-75013 Paris, France
- AP-HP, Groupe hospitalier La Pitié-Salpêtrière, Service de Parasitologie-Mycologie, F-75013 Paris, France
| | - Henri J Vial
- Dynamique des Interactions Membranaires Normales et Pathologiques, CNRS UMR 5235, Université Montpellier II, cc107, Place Eugène Bataillon, 34095 Montpellier, France
| | - Stefan Strobl
- 4SC Discovery GmbH, Am Klopferspitz 19a, 82152 Martinsried, Germany
| | - Cecilia P Sanchez
- Department of Infectious Diseases, Parasitology, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 324, 69120 Heidelberg, Germany
- German Center for Infection Research (DZIF), partner site Heidelberg, 69120 Heidelberg, Germany
| | - Michael Lanzer
- Department of Infectious Diseases, Parasitology, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 324, 69120 Heidelberg, Germany
- German Center for Infection Research (DZIF), partner site Heidelberg, 69120 Heidelberg, Germany
| |
Collapse
|
35
|
Martínez A, Deregnaucourt C, Sinou V, Latour C, Roy D, Schrével J, Sánchez-Delgado RA. Synthesis of an organo-ruthenium aminoquinoline-trioxane hybrid and evaluation of its activity against Plasmodium falciparum and its toxicity toward normal mammalian cells. Med Chem Res 2016. [DOI: 10.1007/s00044-016-1769-6] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
|
36
|
Dana S, Keshri SK, Shukla J, Vikramdeo KS, Mondal N, Mukhopadhyay P, Dhar SK. Design, Synthesis and Evaluation of Bifunctional Acridinine-Naphthalenediimide Redox-Active Conjugates as Antimalarials. ACS OMEGA 2016; 1:318-333. [PMID: 30023479 PMCID: PMC6044610 DOI: 10.1021/acsomega.6b00060] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 05/28/2016] [Accepted: 06/30/2016] [Indexed: 06/08/2023]
Abstract
A novel class of bifunctional molecules was synthesized integrating acridine (Ac) and redox-active naphthalenediimide (NDI) scaffolds directly and through a flexible linker (en). We evaluated in vitro antiplasmodial activity, physicochemical properties, and a possible mode of action. Theoretical studies suggested electronic segmentation between the electron-rich Ac and electron-deficient NDI scaffolds. Orthogonal Ac-NDI molecules showed activities in the micromolar to submicromolar range against a chloroquine (CQ)-sensitive strain of human malaria pathogen Plasmodium falciparum (maximum activity, IC50: 0.419 μM). The flexible Ac-en-NDI molecules were most potent and showed activity in the nanomolar range against both CQ-sensitive (with most effective compounds, IC50: 3.65 and 4.33 nM) as well as CQ-resistant (with most effective compounds, IC50: 52.20 and 28.53 nM) strains of P. falciparum. Significantly, with CQ-resistant strains, the activity of the most effective compounds was 1 order of magnitude better than that of standard drug CQ. Ac-en-NDI-conjugated molecules were significantly more potent than the individual NDI and Ac-based molecules. The structure-activity relationship (SAR) suggests that the flexible spacer (en) linking the Ac and NDI scaffolds plays a vital role in exhibiting improved potency. None of the molecules triggered hemolysis in culture, and the most potent compounds did not show cytotoxicity in vitro against mammalian fibroblast NIH3T3 cells at their respective IC50 values. The other significant outcome of this work is that some of the investigated molecules have the potential to affect multiple processes in the parasite including the hemozoin formation in digestive vacuoles (DVs), mitochondrial membrane potential, and the redox homeostasis of the parasite.
Collapse
Affiliation(s)
- Srikanta Dana
- Supramolecular
and Material Chemistry Lab, School of Physical Sciences, Jawaharlal Nehru University, New Mehrauli Road, 110067 New Delhi, India
- Special
Centre for Molecular Medicine, Jawaharlal
Nehru University, New
Mehrauli Road, 110067 New Delhi, India
| | - Sudhir Kumar Keshri
- Supramolecular
and Material Chemistry Lab, School of Physical Sciences, Jawaharlal Nehru University, New Mehrauli Road, 110067 New Delhi, India
| | - Jyoti Shukla
- Supramolecular
and Material Chemistry Lab, School of Physical Sciences, Jawaharlal Nehru University, New Mehrauli Road, 110067 New Delhi, India
| | - Kunwar Somesh Vikramdeo
- School
of Life Sciences, Jawaharlal Nehru University, New Mehrauli Road, 110067 New Delhi, India
| | - Neelima Mondal
- School
of Life Sciences, Jawaharlal Nehru University, New Mehrauli Road, 110067 New Delhi, India
| | - Pritam Mukhopadhyay
- Supramolecular
and Material Chemistry Lab, School of Physical Sciences, Jawaharlal Nehru University, New Mehrauli Road, 110067 New Delhi, India
| | - Suman Kumar Dhar
- Special
Centre for Molecular Medicine, Jawaharlal
Nehru University, New
Mehrauli Road, 110067 New Delhi, India
| |
Collapse
|
37
|
Tasso B, Novelli F, Tonelli M, Barteselli A, Basilico N, Parapini S, Taramelli D, Sparatore A, Sparatore F. Synthesis and Antiplasmodial Activity of Novel Chloroquine Analogues with Bulky Basic Side Chains. ChemMedChem 2015. [PMID: 26213237 DOI: 10.1002/cmdc.201500195] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Chloroquine is commonly used in the treatment and prevention of malaria, but Plasmodium falciparum, the main species responsible for malaria-related deaths, has developed resistance against this drug. Twenty-seven novel chloroquine (CQ) analogues characterized by a side chain terminated with a bulky basic head group, i.e., octahydro-2H-quinolizine and 1,2,3,4,5,6-hexahydro-1,5-methano-8H-pyrido[1,2-a][1,5]diazocin-8-one, were synthesized and tested for activity against D-10 (CQ-susceptible) and W-2 (CQ-resistant) strains of P. falciparum. Most compounds were found to be active against both strains with nanomolar or sub-micromolar IC50 values. Eleven compounds were found to be 2.7- to 13.4-fold more potent than CQ against the W-2 strain; among them, four cytisine derivatives appear to be of particular interest, as they combine high potency with low cytotoxicity against two human cell lines (HMEC-1 and HepG2) along with easier synthetic accessibility. Replacement of the 4-NH group with a sulfur bridge maintained antiplasmodial activity at a lower level, but produced an improvement in the resistance factor. These compounds warrant further investigation as potential drugs for use in the fight against malaria.
Collapse
Affiliation(s)
- Bruno Tasso
- Dipartimento di Farmacia, Università degli Studi di Genova, Viale Benedetto XV 3, 16131 Genova (Italy).
| | - Federica Novelli
- Dipartimento di Farmacia, Università degli Studi di Genova, Viale Benedetto XV 3, 16131 Genova (Italy)
| | - Michele Tonelli
- Dipartimento di Farmacia, Università degli Studi di Genova, Viale Benedetto XV 3, 16131 Genova (Italy)
| | - Anna Barteselli
- Dipartimento di Scienze Farmaceutiche, Università degli Studi di Milano via Mangiagalli 25, 20133 Milano (Italy)
| | - Nicoletta Basilico
- Dipartimento di Scienze Biomediche, Chirurgiche e Odontoiatriche, Università degli Studi di Milano via C. Pascal 36, 20133 Milano (Italy)
| | - Silvia Parapini
- Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano via C. Pascal, 36, 20133 Milano (Italy)
| | - Donatella Taramelli
- Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano via C. Pascal, 36, 20133 Milano (Italy)
| | - Anna Sparatore
- Dipartimento di Scienze Farmaceutiche, Università degli Studi di Milano via Mangiagalli 25, 20133 Milano (Italy)
| | - Fabio Sparatore
- Dipartimento di Farmacia, Università degli Studi di Genova, Viale Benedetto XV 3, 16131 Genova (Italy)
| |
Collapse
|
38
|
Kaur H, Machado M, de Kock C, Smith P, Chibale K, Prudêncio M, Singh K. Primaquine-pyrimidine hybrids: synthesis and dual-stage antiplasmodial activity. Eur J Med Chem 2015; 101:266-73. [PMID: 26142491 DOI: 10.1016/j.ejmech.2015.06.045] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2015] [Revised: 06/21/2015] [Accepted: 06/22/2015] [Indexed: 10/23/2022]
Abstract
A series of novel pyrimidine-primaquine hybrids were synthesized and their effectiveness against the blood and liver stages of malaria parasites was evaluated. The hybrids displayed enhanced liver stage in vitro activity against P. berghei liver stage infection.
Collapse
Affiliation(s)
- Hardeep Kaur
- Department of Chemistry, UGC-Centre for Advanced Studies-II, Guru Nanak Dev University, Amritsar 143005, India
| | - Marta Machado
- Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-028 Lisboa, Portugal
| | - Carmen de Kock
- Division of Pharmacology, Department of Medicine, University of Cape Town, Observatory 7925, South Africa
| | - Peter Smith
- Division of Pharmacology, Department of Medicine, University of Cape Town, Observatory 7925, South Africa
| | - Kelly Chibale
- Department of Chemistry, South African Medical Research Council Drug Discovery and Development Research Unit, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Rondebosch 701, South Africa
| | - Miguel Prudêncio
- Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-028 Lisboa, Portugal
| | - Kamaljit Singh
- Department of Chemistry, UGC-Centre for Advanced Studies-II, Guru Nanak Dev University, Amritsar 143005, India.
| |
Collapse
|
39
|
Kaur H, Balzarini J, de Kock C, Smith PJ, Chibale K, Singh K. Synthesis, antiplasmodial activity and mechanistic studies of pyrimidine-5-carbonitrile and quinoline hybrids. Eur J Med Chem 2015; 101:52-62. [PMID: 26114811 DOI: 10.1016/j.ejmech.2015.06.024] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2014] [Revised: 05/19/2015] [Accepted: 06/08/2015] [Indexed: 12/26/2022]
Abstract
A series of hybrids comprising of 5-cyanopyrimidine and quinoline moiety were synthesized and tested for in vitro antiplasmodial activity against NF54 and Dd2 strains of Plasmodium falciparum. Hybrid bearing m-nitrophenyl substituent at C-4 of pyrimidine displayed the highest antiplasmodial activity [IC50 = 56 nM] against the CQ(R) (Dd2) strain, which is four-fold greater than CQ.
Collapse
Affiliation(s)
- Hardeep Kaur
- Department of Chemistry, UGC-Centre of Advance Study-II, Guru Nanak Dev University, Amritsar 143005, India
| | - Jan Balzarini
- Rega Institute for Medical Research, KU Leuven, 10 Minderbroedersstraat, B-3000 Leuven, Belgium
| | - Carmen de Kock
- Division of Pharmacology, Department of Medicine, University of Cape Town, Observatory 7925, South Africa
| | - Peter J Smith
- Division of Pharmacology, Department of Medicine, University of Cape Town, Observatory 7925, South Africa
| | - Kelly Chibale
- Department of Chemistry, South African Medical Research Council Drug Discovery and Development Research Unit, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Rondebosch 7701, South Africa
| | - Kamaljit Singh
- Department of Chemistry, UGC-Centre of Advance Study-II, Guru Nanak Dev University, Amritsar 143005, India.
| |
Collapse
|
40
|
Soares RR, da Silva JMF, Carlos BC, da Fonseca CC, de Souza LSA, Lopes FV, de Paula Dias RM, Moreira POL, Abramo C, Viana GHR, de Pila Varotti F, da Silva AD, Scopel KKG. New quinoline derivatives demonstrate a promising antimalarial activity against Plasmodium falciparum in vitro and Plasmodium berghei in vivo. Bioorg Med Chem Lett 2015; 25:2308-13. [PMID: 25920564 DOI: 10.1016/j.bmcl.2015.04.014] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2015] [Revised: 04/01/2015] [Accepted: 04/08/2015] [Indexed: 11/19/2022]
Abstract
Malaria continues to be an important public health problem in the world. Nowadays, the widespread parasite resistance to many drugs used in antimalarial therapy has made the effective treatment of cases and control of the disease a constant challenge. Therefore, the discovery of new molecules with good antimalarial activity and tolerance to human use can be really important in the further treatment of the disease. In this study we have investigated the antiplasmodial activity of 10 synthetic compounds derived from quinoline, five of them combined to sulfonamide and five to the hydrazine or hydrazide group. The compounds were evaluated according to their cytotoxicity against HepG2 and HeLa cell lines, their antimalarial activity against CQ-sensitive and CQ-resistant Plasmodium falciparum strains and, finally, their schizonticide blood action in mice infected with Plasmodium berghei NK65. The compounds exhibited no cytotoxic action in HepG2 and HeLa cell lines when tested up to a concentration of 100 μg/mL. In addition, the hydrazine or hydrazide derivative compounds were less cytotoxic against cell lines and more active against CQ-sensitive and CQ-resistant P. falciparum strains, showing high SI (>1000 when SI was calculated using the CC50 from the 3D7 strain as reference). When tested in vivo, the hydrazine derivative 1f compound showed activity against the development of blood parasites similar to that observed with CQ, the reference drug. Interestingly, the 1f compound demonstrated the best LipE value (4.84) among all those tested in vivo. Considering the in vitro and in vivo activities of the compounds studied here and the LipE values, we believe the 1f compound to be the most promising molecule for further studies in antimalarial chemotherapy.
Collapse
Affiliation(s)
- Roberta Reis Soares
- Departamento de Parasitologia, Microbiologia e Imunologia, Universidade Federal de Juiz de Fora, Rua José Lourenço Kelmer s/n, Martelos, 36036-900 Juiz de Fora, MG, Brazil.
| | - José Marcio Fernandes da Silva
- Departamento de Parasitologia, Microbiologia e Imunologia, Universidade Federal de Juiz de Fora, Rua José Lourenço Kelmer s/n, Martelos, 36036-900 Juiz de Fora, MG, Brazil.
| | - Bianca Cecheto Carlos
- Instituto de Biotecnologia (IBTEC), Universidade Estadual Paulista, Alameda dos Tecomarias, s/n, 18607-440 Botucatu, SP, Brazil.
| | - Camila Campos da Fonseca
- Departamento de Parasitologia, Microbiologia e Imunologia, Universidade Federal de Juiz de Fora, Rua José Lourenço Kelmer s/n, Martelos, 36036-900 Juiz de Fora, MG, Brazil.
| | - Laila Salomé Araújo de Souza
- Departamento de Parasitologia, Microbiologia e Imunologia, Universidade Federal de Juiz de Fora, Rua José Lourenço Kelmer s/n, Martelos, 36036-900 Juiz de Fora, MG, Brazil.
| | - Fernanda Valério Lopes
- Departamento de Parasitologia, Microbiologia e Imunologia, Universidade Federal de Juiz de Fora, Rua José Lourenço Kelmer s/n, Martelos, 36036-900 Juiz de Fora, MG, Brazil.
| | - Rafael Mafra de Paula Dias
- Instituto de Química de São Carlos, Universidade de São Paulo. Avenida João Dagnone, n° 1100, Jardim Santa Angelina, 13563-120 São Carlos, SP, Brazil.
| | - Paulo Otávio Lourenço Moreira
- Núcleo de Pesquisa em Química Biológica (NQBio), Universidade de São João Del Rei, Rua Sebastião Gonçalves Coelho, Chanadour, 35501-296 Divinópolis, MG, Brazil.
| | - Clarice Abramo
- Departamento de Parasitologia, Microbiologia e Imunologia, Universidade Federal de Juiz de Fora, Rua José Lourenço Kelmer s/n, Martelos, 36036-900 Juiz de Fora, MG, Brazil.
| | - Gustavo Henrique Ribeiro Viana
- Núcleo de Pesquisa em Química Biológica (NQBio), Universidade de São João Del Rei, Rua Sebastião Gonçalves Coelho, Chanadour, 35501-296 Divinópolis, MG, Brazil.
| | - Fernando de Pila Varotti
- Núcleo de Pesquisa em Química Biológica (NQBio), Universidade de São João Del Rei, Rua Sebastião Gonçalves Coelho, Chanadour, 35501-296 Divinópolis, MG, Brazil.
| | - Adilson David da Silva
- Departamento de Química, Instituto de Ciências Exatas, Universidade Federal de Juiz de Fora, Rua José Lourenço Kelmer s/n, Martelos, 36036-900 Juiz de Fora, MG, Brazil.
| | - Kézia Katiani Gorza Scopel
- Departamento de Parasitologia, Microbiologia e Imunologia, Universidade Federal de Juiz de Fora, Rua José Lourenço Kelmer s/n, Martelos, 36036-900 Juiz de Fora, MG, Brazil; Departamento of Global Health, University of South Florida, 3720 Spectrun Blvd, suit 304, Tampa, FL 33612, USA.
| |
Collapse
|
41
|
From hybrid compounds to targeted drug delivery in antimalarial therapy. Bioorg Med Chem 2015; 23:5120-30. [PMID: 25913864 DOI: 10.1016/j.bmc.2015.04.017] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2015] [Revised: 04/01/2015] [Accepted: 04/07/2015] [Indexed: 11/21/2022]
Abstract
The discovery of new drugs to treat malaria is a continuous effort for medicinal chemists due to the emergence and spread of resistant strains of Plasmodium falciparum to nearly all used antimalarials. The rapid adaptation of the malaria parasite remains a major limitation to disease control. Development of hybrid antimalarial agents has been actively pursued as a promising strategy to overcome the emergence of resistant parasite strains. This review presents the journey that started with simple combinations of two active moieties into one chemical entity and progressed into a delivery/targeted system based on major antimalarial classes of drugs. The rationale for providing different mechanisms of action against a single or additional targets involved in the multiple stages of the parasite's life-cycle is highlighted. Finally, a perspective for this polypharmacologic approach is presented.
Collapse
|
42
|
Kumar S, Singh RK, Patial B, Goyal S, Bhardwaj TR. Recent advances in novel heterocyclic scaffolds for the treatment of drug-resistant malaria. J Enzyme Inhib Med Chem 2015; 31:173-86. [PMID: 25775094 DOI: 10.3109/14756366.2015.1016513] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
Malaria is a major public health problem all over the world, particularly in tropical and subtropical countries due to the development of resistance and most deadly infection is caused by Plasmodium falciparum. There is a direct need for the discovery of new drugs with unique structures and mechanism of action to treat sensitive and drug-resistant strains of various plasmodia for radical cure of this disease. Traditional compounds such as quinine and related derivatives represent a major source for the development of new drugs. This review presents recent modifications of 4-aminoquinoline and 8-aminoquinolone rings as leads to novel active molecules which are under clinical trials. The review also encompasses the other heterocyclic compounds emerged as potential antimalarial agents with promising results such as acridinediones and acridinone analogues, pyridines and quinolones as antimalarials. Miscellaneous heterocyclics such as tetroxane derivatives, indole derivatives, imidazolopiperazine derivatives, biscationic choline-based compounds and polymer-linked combined antimalarial drugs are also discussed. At last brief introduction to heterocyclics in natural products is also reviewed. Most of them have been under clinical trials and found to be promising in the treatment of drug-resistant strains of Plasmodium and others can be explored for the same purpose.
Collapse
Affiliation(s)
- Sahil Kumar
- a Department of Pharmaceutical Chemistry , Indo-Soviet Friendship (I.S.F.) College of Pharmacy , Moga , Punjab , India .,b Faculty of Pharmacy , Punjab Technical University , Jalandhar, Kapurthala , India
| | - Rajesh K Singh
- c Department of Pharmaceutical Chemistry , Shivalik College of Pharmacy , Nangal, Dist. Rupnagar , Punjab , India , and
| | - Babita Patial
- a Department of Pharmaceutical Chemistry , Indo-Soviet Friendship (I.S.F.) College of Pharmacy , Moga , Punjab , India
| | - Sachin Goyal
- a Department of Pharmaceutical Chemistry , Indo-Soviet Friendship (I.S.F.) College of Pharmacy , Moga , Punjab , India
| | - T R Bhardwaj
- a Department of Pharmaceutical Chemistry , Indo-Soviet Friendship (I.S.F.) College of Pharmacy , Moga , Punjab , India .,d Department of Pharmaceutical Chemistry , University Institute of Pharmaceutical Sciences, Panjab University , Chandigarh , India
| |
Collapse
|
43
|
Sonawane DP, Persico M, Corbett Y, Chianese G, Di Dato A, Fattorusso C, Taglialatela-Scafati O, Taramelli D, Trombini C, Dhavale DD, Quintavalla A, Lombardo M. New antimalarial 3-methoxy-1,2-dioxanes: optimization of cellular pharmacokinetics and pharmacodynamics properties by incorporation of amino and N-heterocyclic moieties at C4. RSC Adv 2015. [DOI: 10.1039/c5ra10785g] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
A new series of 3-methoxy-1,2-dioxanes containing an amino moiety at C4 was synthesized, displaying nanomolar antimalarial activity without being cytotoxic.
Collapse
|
44
|
Raj R, Land KM, Kumar V. 4-Aminoquinoline-hybridization en route towards the development of rationally designed antimalarial agents. RSC Adv 2015. [DOI: 10.1039/c5ra16361g] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
Abstract
Recent developments in 4-aminoquinoline-hybridization, as an attractive strategy for averting and delaying the drug resistance along with improvement in efficacy of new antimalarials, are described.
Collapse
Affiliation(s)
- Raghu Raj
- Department of Chemistry
- Guru Nanak Dev University
- Amritsar-143005
- India
| | - Kirkwood M. Land
- Department of Biological Sciences
- University of the Pacific
- Stockton
- USA
| | - Vipan Kumar
- Department of Chemistry
- Guru Nanak Dev University
- Amritsar-143005
- India
| |
Collapse
|
45
|
Tripathi M, Khan SI, Thakur A, Ponnan P, Rawat DS. 4-Aminoquinoline-pyrimidine-aminoalkanols: synthesis, in vitro antimalarial activity, docking studies and ADME predictions. NEW J CHEM 2015. [DOI: 10.1039/c5nj00094g] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
4-Aminoquinoline-pyrimidine-aminoalkanols displaying good in vitro antimalarial activities against both CQ-sensitive and -resistant strains of P. falciparum, together with favourable resistance-indices and the predicted ADME properties, are reported.
Collapse
Affiliation(s)
- Mohit Tripathi
- Department of Chemistry
- University of Delhi
- Delhi 110007
- India
| | - Shabana I. Khan
- National Centre for Natural Products Research
- University of Mississippi
- MS-38677
- USA
| | - Anuj Thakur
- Department of Chemistry
- University of Delhi
- Delhi 110007
- India
| | - Prija Ponnan
- Department of Chemistry
- University of Delhi
- Delhi 110007
- India
| | - Diwan S. Rawat
- Department of Chemistry
- University of Delhi
- Delhi 110007
- India
| |
Collapse
|
46
|
Abstract
In this article strategies for the design and synthesis of natural product analogues are summarized and illustrated with some selected examples.
Collapse
Affiliation(s)
- Martin E. Maier
- Institut für Organische Chemie
- Eberhard Karls Universität Tübingen
- 72076 Tübingen
- Germany
| |
Collapse
|
47
|
Teixeira C, Vale N, Pérez B, Gomes A, Gomes JRB, Gomes P. "Recycling" classical drugs for malaria. Chem Rev 2014; 114:11164-220. [PMID: 25329927 DOI: 10.1021/cr500123g] [Citation(s) in RCA: 85] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Affiliation(s)
- Cátia Teixeira
- Centro de Investigação em Química da Universidade do Porto, Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade do Porto , P-4169-007 Porto, Portugal.,CICECO, Departamento de Química, Universidade de Aveiro , P-3810-193 Aveiro, Portugal
| | - Nuno Vale
- Centro de Investigação em Química da Universidade do Porto, Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade do Porto , P-4169-007 Porto, Portugal
| | - Bianca Pérez
- Centro de Investigação em Química da Universidade do Porto, Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade do Porto , P-4169-007 Porto, Portugal
| | - Ana Gomes
- Centro de Investigação em Química da Universidade do Porto, Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade do Porto , P-4169-007 Porto, Portugal
| | - José R B Gomes
- CICECO, Departamento de Química, Universidade de Aveiro , P-3810-193 Aveiro, Portugal
| | - Paula Gomes
- Centro de Investigação em Química da Universidade do Porto, Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade do Porto , P-4169-007 Porto, Portugal
| |
Collapse
|
48
|
Abstract
Targeting the redox metabolism of Plasmodium falciparum to create a fatal overload of oxidative stress is a route to explore the discovery of new antimalarial drugs. There are three main possibilities to target the redox metabolism of P. falciparum at the erythrocytic stage: selective targeting and inhibition of a redox P. falciparum protein or enzyme; oxidant drugs targeting essential parasite components and heme by-products; and redox cycler drugs targeting the parasitized red blood cell. Oxidants and redox cycler agents, with or without specific targets, may disrupt the fragile parasitized erythrocyte redox-dependent architecture given that: redox equilibrium plays a vital role at the erythrocytic stage; P. falciparum possesses major NADPH-dependent redox systems, such as glutathione and thioredoxin ones; and the protein-NADPH-dependent phosphorylation-dephosphorylation process is involved in building new permeation pathways and channels for the nutrient-waste import-export traffic of the parasite.
Collapse
|
49
|
Fisher GM, Tanpure RP, Douchez A, Andrews KT, Poulsen SA. Synthesis and Evaluation of Antimalarial Properties of Novel 4-Aminoquinoline Hybrid Compounds. Chem Biol Drug Des 2014; 84:462-72. [DOI: 10.1111/cbdd.12335] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2014] [Revised: 04/04/2014] [Accepted: 04/04/2014] [Indexed: 01/24/2023]
Affiliation(s)
- Gillian M. Fisher
- Eskitis Institute for Drug Discovery; Griffith University; Don Young Road Nathan Qld 4111 Australia
| | - Rajendra P. Tanpure
- Eskitis Institute for Drug Discovery; Griffith University; Don Young Road Nathan Qld 4111 Australia
| | - Antoine Douchez
- Eskitis Institute for Drug Discovery; Griffith University; Don Young Road Nathan Qld 4111 Australia
| | - Katherine T. Andrews
- Eskitis Institute for Drug Discovery; Griffith University; Don Young Road Nathan Qld 4111 Australia
| | - Sally-Ann Poulsen
- Eskitis Institute for Drug Discovery; Griffith University; Don Young Road Nathan Qld 4111 Australia
| |
Collapse
|
50
|
Angulo-Barturen I, Ferrer S. Humanised models of infection in the evaluation of anti-malarial drugs. DRUG DISCOVERY TODAY. TECHNOLOGIES 2014; 10:e351-7. [PMID: 24050131 DOI: 10.1016/j.ddtec.2012.07.003] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Humanised mice have a crucial role for drug discovery in malaria, which is the most important parasitic disease in the world and is caused by protozoa of the genus Plasmodium that selectively infect human hepatocytes and erythrocytes. There are currently reliable humanised murine models for hepatic and erythrocytic stages of Plasmodium falciparum, which is the most pathogenic malarial species. These models are useful in the evaluation of drugs for malaria prevention and treatment, notably in exploiting the thousands of antimalarial hits discovered. The development of a humanised model for Plasmodium vivax and the validation of the P. falciparum models to inform optimal clinical studies are the next key goals to be achieved.
Collapse
|